What is Canizol?
Canizol is used to treat infections caused by a fungus or yeast. It works by killing the fungus or yeast or preventing its growth.
Canizol cream is used to treat:
- Athlete's foot (tinea pedis; ringworm of the foot);
- Ringworm of the body (tinea corporis);
- Ringworm of the groin (tinea cruris; jock itch);
- Seborrheic dermatitis;
- "Sun fungus" (tinea versicolor; pityriasis versicolor); and
- Yeast infection of the skin (cutaneous candidiasis).
Canizol foam or gel is used to treat seborrheic dermatitis (scaly areas on your skin or scalp).
Canizol 1% shampoo is used to treat dandruff.
Canizol 2% shampoo is used to treat "sun fungus" (tinea versicolor; pityriasis versicolor).
Canizol may also be used for other fungus infections of the skin as determined by your doctor.
Most forms of Canizol are available only with your doctor's prescription. Some forms are available without a prescription. However, your doctor may have special instructions on the proper use for your medical condition.
Canizol indications
Canizol is an imidazole antifungal administered topically or by mouth. It is given by mouth in chronic mucocutaneous or vaginal candidiasis, in fungal infections of the gastrointestinal tract, in dermatophyte infections of the skin and fingernails not responding to topical treatment, and in systemic infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis.
It has been given for the prophylaxis of fungal infections in immunocompromised patients, although fluconazole or itraconazole are usually preferred. It has been recommended that, because of its erratic absorption and slow therapeutic response, Canizol should not be used for the treatment of life-threatening fungal infections, including fungal meningitis, or for severe infections in immunocompromised patients. Also, because of the risk of hepatotoxicity the use of Canizol in nonsystemic fungal infections tends to be restricted to serious infections resistant to other treatment.
How should I use Canizol?
Use Canizol gel as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Canizol gel. Talk to your pharmacist if you have questions about this information.
- Wash your hands before and immediately after using Canizol gel.
- Spread a thin layer of Canizol gel onto the affected area with the tips of your fingers. Gently rub it in. Be sure to cover the entire affected area and the healthy skin around it.
- Do not touch your eyes or nose while you are applying Canizol gel.
- Wait for at least 20 minutes after you apply Canizol gel before you apply makeup or sunscreen.
- Do not wash the area where you applied Canizol gel for at least 3 hours after you apply it.
- If you miss a dose of Canizol gel, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Canizol gel.
Uses of Canizol in details
Use: Labeled Indications
Fungal infections (systemic):
US labeling: Treatment of susceptible systemic fungal infections, including blastomycosis, histoplasmosis, paracoccidioidomycosis, coccidioidomycosis, and chromomycosis in patients who have failed or who are intolerant to other antifungal therapies
Limitations of use: Canizol should only be used when other effective antifungal therapy is not available or tolerated and the potential benefits outweigh the potential risks. Canizol tablets are not indicated for the treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections.
Canadian labeling: Treatment of serious or life-threatening systemic fungal infections (eg, systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis, paracoccidioidomycosis, histoplasmosis, and chromomycosis) where alternate therapy is inappropriate or ineffective; may be considered for severe dermatophytoses unresponsive to other therapy
Off Label Uses
Cushing syndrome
Data from a retrospective multicenter study support the use of Canizol in the management of patients with Cushing disease. The study authors found the side effects of Canizol to be acceptable; however, close monitoring of liver enzymes is advised. Additional trials may be necessary to further define the role of Canizol in this condition.
Based on the Endocrine Society
Canizol description
Canizol contains the following ingredients: D-Water, maltodextrin (corn), partially hydrolyzed sodium caseinate, lactalbumin hydrolysate, canola oil, medium-chain triglycerides (fractionated coconut oil), L-arginine, corn oil, magnesium chloride, potassium citrate, tribasic calcium phosphate, citric acid, soy lecithin, ascorbic acid, dibasic potassium phosphate, choline chloride, carrageenan, potassium chloride, taurine, L-carnitine, zinc sulfate, ferrous sulfate, α-tocopheryl acetate, niacinamide, calcium pantothenate, manganese sulfate, β-carotene, cupric sulfate, thiamine chloride HCl, pyridoxine HCl, riboflavin, vitamin A palmitate, folic acid, biotin, chromium chloride, sodium molybdate, potassium iodide, sodium selenate, phylloquinone, cyanocobalamin and vitamin D3.
Canizol is a ready-to-feed enteral product as a supplemental or sole-source nutrition complete and balanced nutrition for tube feeding. It is calorie dense at 1.3 cal/mL and contains a protein system of partially hydrolyzed proteins, including peptides and amino acids, to utilize the dual absorption system of the gut. Canizol is lactose- and gluten-free.
Caloric Distribution: See Table 1.
Analysis: See Table 2.
Canizol dosage
Canizol Dosage
Generic name: Canizol 200mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
There should be laboratory as well as clinical documentation of infection prior to starting Canizol therapy. The usual duration of therapy for systemic infection is 6 months. Treatment should be continued until active fungal infection has subsided.
Adults
The recommended starting dose of Canizol® (Canizol) Tablets is a single daily administration of 200 mg (one tablet). If clinical responsiveness is insufficient within the expected time, the dose of Canizol® Tablets may be increased to 400 mg (two tablets) once daily.
Children
In small numbers of children over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg has been used. Canizol® Tablets have not been studied in children under 2 years of age.
More about Canizol (Canizol)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Espanol
- 4 Reviews - Add your own review/rating
Consumer resources
- Canizol
- Canizol (Advanced Reading)
Professional resources
- Canizol (AHFS Monograph)
- Canizol (FDA)
Other formulations
- Canizol
Topical
- Canizol A-D
Related treatment guides
- Blastomycosis
- Chromomycosis
- Coccidioidomycosis
- Histoplasmosis
- Paracoccidioidomycosis
Canizol interactions
See also:
What other drugs will affect Canizol?
Canizol is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of Canizol Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.
Canizol Tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine.
Canizol inhibits the metabolism of astemizole. Canizol potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
Canizol Tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
Coadministration of Canizol Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
It is, therefore, advisable to monitor digoxin concentrations in patients receiving Canizol.
When taken orally, imidazole compounds like Canizol may enhance the anticoagulant effect of coumarin-like drugs.
a potential interaction involving the latter agents when used concomitantly with Canizol Tablets (an imidazole) can not be ruled out.
Concomitant administration of Canizol Tablets with phenytoin may alter the metabolism of one or both of the drugs.
Concomitant administration of rifampin with Canizol Tablets reduces the blood levels of the latter. INH (isoniazid) is also reported to affect Canizol concentrations adversely.
Canizol side effects
See also:
What are the possible side effects of Canizol?
Topically applied Canizol appears to have a low order of toxicity and is generally well tolerated. Adverse effects have been reported in up to 5% of patients receiving Canizol 2% cream and have consisted principally of local reactions such as severe irritation, pruritus, and stinging. A painful allergic reaction, consisting of localized swelling and inflammation, occurred in at least one patient receiving Canizol 2% cream and contact dermatitis occurred in another.
In several studies evaluating the potential of topical Canizol for causing dermal irritation, contact sensitization, or phototoxic or photoallergenic reactions in healthy adults, topical application of Canizol 2% cream caused mild transient erythema in some individuals, but did not cause contact sensitization of the delayed hypersensitivity type, irritation, phototoxicity, or photocontact sensitization.
Contact dermatitis has been reported following topical application of imidazole-derivative azole antifungals (e.g., clotrimazole, econazole, miconazole, oxiconazole, sulconazole, tioconazole). Cross-sensitization appears to occur among the imidazole derivatives; however, cross-sensitivity appears to be unpredictable. The fact that patients with contact sensitivity to one imidazole-derivative azole antifungal may be sensitive to other similar drugs should be considered.
Although hepatotoxicity has occurred during treatment with oral Canizol, it is unlikely that this adverse effect would occur with Canizol 2% cream since the drug does not appear to be appreciably absorbed following topical application to skin.
Adverse effects reported in patients receiving topical Canizol 2% as a shampoo applied to the skin include pruritus, application site reaction, and dry skin. Adverse effects reported in patients receiving Canizol shampoo to the scalp include increased hair loss, irritation, abnormal hair texture, scalp pustules, dry skin, pruritus, and oiliness or dryness of the hair and scalp. In some patients with permanently waved (“permed”) hair, use of Canizol 2% shampoo resulted in loss of the curl.
Canizol contraindications
See also:
What is the most important information I should know about Canizol?
Drug Interactions
Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with Canizol® Tablets. Coadministration with Canizol can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.
Additionally, the following other drugs are contraindicated with Canizol® Tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine.
Enhanced Sedation
Coadministration of Canizol® Tablets with oral midazolam, oral triazolam or alprazolam has resulted in elevated plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. Concomitant administration of Canizol® Tablets with oral triazolam, oral midazolam or alprazolam is contraindicated.
Myopathy
Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with Canizol® Tablets.
Ergotism
Concomitant administration of ergot alkaloids such as dihydroergotamine and ergotamine with Canizol® Tablets is contraindicated.
Liver Disease
The use of Canizol® Tablets is contraindicated in patients with acute or chronic liver disease.
Hypersensitivity
Canizol® is contraindicated in patients who have shown hypersensitivity to the drug.
Active ingredient matches for Canizol:
Ketoconazole in Finland.
References
- DailyMed. "KETOCONAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "ketoconazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "ketoconazole". http://www.drugbank.ca/drugs/DB01026 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Canizol are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Canizol. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
